ARTICLE | Strategy
Genmab’s second act
Why Genmab thinks the time is right to build a commercial organization
December 9, 2017 12:29 AM UTC
For the second time, Genmab A/S finds itself at the threshold of transitioning into a commercial biotech and is planning to change its partnering approach to retain a more significant portion of the value of its pipeline products.
At face value, the circumstances might appear similar to the first time the biotech took the leap. In 2008, when Genmab began laying a path to market, it had three assets in Phase III testing. It had an option to co-promote one of them in the U.S. and Nordic countries, had regained rights to one and had yet to partner the third...
BCIQ Company Profiles